# Remdesivir in COVID-19: pros and cons

## TL;DR

This paper reviews remdesivir's effectiveness and limitations in treating COVID-19, including its use in patients with congenital heart disease.

## Contribution

The paper evaluates remdesivir's role in treating COVID-19 and identifies a research gap regarding its use in patients with congenital heart disease.

## Key findings

- Remdesivir shortens recovery time and lowers mortality risk in early-stage or mild to moderate COVID-19.
- Safety in patients with renal impairment was confirmed, leading to an FDA label update.
- Uncertain effects of remdesivir in patients with congenital heart disease highlight a need for further research.

## Abstract

Beginning in late 2019, the COVID-19 pandemic caused by SARS-CoV-2 rapidly evolved into a global health crisis. High rates of severe illness, hospitalizations, and long-term complications highlighted an urgent need for effective therapeutic agents. This necessity drove unprecedented efforts in drug discovery and repurposing. Remdesivir, developed by Gilead Sciences in 2009, was initially designed as a broad-spectrum antiviral targeting Ebola virus disease. Following observations of broad antiviral activity against coronaviruses, remdesivir was granted Emergency Use Authorization by the FDA in May 2020 for hospitalized patients with severe COVID-19. The FDA subsequently issued full approval in October 2020, expanding remdesivir’s use to hospitalized adults and pediatric patients aged 12 years or older and weighing at least 40 kg.

This paper aims to assess the advantages and limitations of remdesivir in the treatment of COVID-19, drawing on evidence from clinical trials and examining its application in patients with congenital heart disease (CHD).

The literature review was conducted until September 2025 using PubMed and Google Scholar searching for recent clinical trials in addition to relevant reviews.

Remdesivir has been shown to shorten recovery time and lower mortality risk, particularly in patients at an early stage of infection with mild disease severity or requiring oxygen support. Although early guidelines advised against its use in patients with severe renal impairment, subsequent studies confirmed its safety prompting an FDA label update to allow use regardless of renal function. While some trials reported limited effects, the overall body of evidence supports remdesivir’s role in improving clinical outcomes in COVID-19 treatment. In patients with CHD, the uncertain effects of both COVID-19 and remdesivir highlight a key research gap, emphasizing the need to refine existing therapies while following National Institutes of Health (NIH) treatment guidelines.